276
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Effect of Adalimumab on Peripheral Blood Mononuclear Cells in Non-Infectious Uveitis

, MD, , PhD, , MD, , MD, , PhD & , MD
Pages 330-337 | Received 12 Apr 2017, Accepted 29 Aug 2017, Published online: 11 Oct 2017

REFERENCES

  • Castiblanco C, Meese H, Foster CS. Treatment of pediatric uveitis with adalimumab: the MERSI experience. J Aapos. 2016;20(2):145–147.
  • Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943.
  • Vallet H, Seve P, Biard L, et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the french uveitis network. Arthritis Rheumatol. 2016;68(6):1522–1530.
  • Balevic SJ, Rabinovich CE. Profile of adalimumab and its potential in the treatment of uveitis. Drug Des Devel Ther. 2016;10:2997–3003.
  • Busch M, Bauer D, Hennig M, Wasmuth S, Thanos S, Heiligenhaus A. Effects of systemic and intravitreal TNF-alpha inhibition in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2013;54(1):39–46.
  • Calleja S, Cordero-Coma M, Rodriguez E, Llorente M, Franco M. Ruiz de Morales JG. Adalimumab specifically induces CD3(+) CD4(+) CD25(high) Foxp3(+) CD127(-) T-regulatory cells and decreases vascular endothelial growth factor plasma levels in refractory immuno-mediated uveitis: a non-randomized pilot intervention study. Eye (Lond). 2012;26(3):468–477.
  • Herenius MM, Thurlings RM, Wijbrandts CA, et al. Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab. Ann Rheum Dis. 2011;70(6):1160–1162.
  • Vos AC, Wildenberg ME, Duijvestein M, Verhaar AP, Van Den Brink GR, Hommes DW. Anti-tumor necrosis factor-alpha antibodies induce regulatory macrophages in an Fc region-dependent manner. Gastroenterology. 2011;140(1):221–230.
  • Arora T, Padaki R, Liu L, et al. Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009;45(2):124–131.
  • Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. Molecular mechanisms of action of anti-TNF-alpha agents: comparison among therapeutic TNF-alpha antagonists. Cytokine. 2016. doi: 10.1016/j.cyto.2016.08.014.
  • Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Reviews Immunol. 2002;2(2):116–126.
  • Weinhage T, Däbritz J, Brockhausen A, et al. Granulocyte macrophage colony-stimulating factor–activated CD39+/CD73+ murine monocytes modulate intestinal inflammation via induction of regulatory T cells. Cell Mol Gastroenterol Hepatol. 2015;1(4):433–449.
  • Murphy CC. Systemic CD4+ T cell phenotype and activation status in intermediate uveitis. Br J Ophthalmol. 2004;88(3):412–416.
  • Kilmartin DJ, Fletcher ZJ, Almeida JA, Liversidge J, Forrester JV, Dick AD. CD69 expression on peripheral CD4+ T cells parallels disease activity and is reduced by mycophenolate mofetil therapy in uveitis. Invest Ophthalmol Vis Sci. 2001;42(6):1285–1292.
  • Dick AD. Immune mechanisms of uveitis: insights into disease pathogenesis and treatment. Int Ophthalmol Clin. 2000;40(2):1–18.
  • Walscheid K, Weinhage T, Foell D, Heinz C, Kasper M, Heiligenhaus A. Phenotypic changes of peripheral blood mononuclear cells upon corticosteroid treatment in idiopathic intermediate uveitis. Clin Immunology. 2016;173:27–31.
  • Nguyen DX, Ehrenstein MR. Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis. J Exp Med. 2016;213(7):1241–1253.
  • Overgaard NH, Jung JW, Steptoe RJ, Wells JW. CD4+/CD8+ double-positive T cells: more than just a developmental stage? J Leukoc Biol. 2015;97(1):31–38.
  • Quandt D, Rothe K, Scholz R, Baerwald CW, Wagner U. Peripheral CD4CD8 double positive T cells with a distinct helper cytokine profile are increased in rheumatoid arthritis. PloS One. 2014;9(3):e93293.
  • Parel Y, Chizzolini C. CD4+ CD8+ double positive (DP) T cells in health and disease. Autoimmun Rev. 2004;3(3):215–220.
  • Kessel C, Holzinger D, Foell D. Phagocyte-derived S100 proteins in autoinflammation: putative role in pathogenesis and usefulness as biomarkers. Clin Immunology. 2013;147(3):229–241.
  • Walscheid K, Heiligenhaus A, Holzinger D, et al. Elevated S100A8/A9 and s100a12 serum levels reflect intraocular inflammation in juvenile idiopathic arthritis-associated uveitis: results from a pilot study. Invest Ophthalmol Vis Sci. 2015;56(13):7653–7660.
  • Olson JA, Forrester M, Clohessy PA, Golden BE, Herriot R, Forrester JV. Calprotectin is raised in endogenous posterior uveitis. Ocul Immunol Inflamm. 1996;4(2):91–98.
  • Boschetti G, Garnero P, Moussata D, et al. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn’s disease. Inflamm Bowel Dis. 2015;21(2):331–336.
  • Nordal HH, Brun JG, Halse AK, Jonsson R, Fagerhol MK, Hammer HB. The neutrophil protein S100A12 is associated with a comprehensive ultrasonographic synovitis score in a longitudinal study of patients with rheumatoid arthritis treated with adalimumab. BMC Musculoskelet Disord. 2014;15:335.
  • Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J. Ophthalmol. 2005;140:509–516.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.